274 related articles for article (PubMed ID: 16532090)
1. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
2. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
[TBL] [Abstract][Full Text] [Related]
3. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
4. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
Nicolini A; Ferrari P; Sagripanti A; Carpi A
Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
6. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
Yildiz M; Oral B; Bozkurt M; Cobaner A
Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
9. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
[TBL] [Abstract][Full Text] [Related]
10. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
[TBL] [Abstract][Full Text] [Related]
11. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
[TBL] [Abstract][Full Text] [Related]
12. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
[TBL] [Abstract][Full Text] [Related]
15. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
[TBL] [Abstract][Full Text] [Related]
16. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
Nicolini A; Carpi A; Ferrari P; Pieri L
Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
[TBL] [Abstract][Full Text] [Related]
17. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
[TBL] [Abstract][Full Text] [Related]
18. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
19. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
20. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]